Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Intron A Redipen

Intron A Redipen is a medicine containing the active ingredient(s) interferon alfa-2b. On this page you will find out more about Intron A Redipen, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: interferon alfa-2b

Pack size information

Please select the pack size from the options directly below to view information on the medicine.

Information for medicine and pack size:
Intron A Redipen 60 million units/1.2 mL injection solution, 1.2 mL

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

Hairy cell leukaemia: for the treatment of hairy cell leukaemia in splenectomised or non-splenectomised patients. Kaposi's sarcoma in AIDS: for the treatment of Kaposi's sarcoma in patients with acquired immune deficiency syndrome (AIDS). Chronic myelogenous leukaemia: for the treatment of Philadelphia chromosome positive chronic myelogenous leukaemia in the chronic phase. Multiple myeloma: for the maintenance of control of multiple myeloma once control has been achieved by chemotherapy. The effect on overall survival has not as yet been determined. Follicular non-Hodgkin's lymphoma: as an adjuvant treatment of high tumour burden Stage III or IV follicular non-Hodgkin's lymphoma in conjunction with an appropriate chemotherapy regimen. In controlled clinical trials in which efficacy was demonstrated, anthracycline chemotherapy was employed. Malignant melanoma: as an adjuvant therapy of malignant melanoma following surgery in patients who are at high risk of recurrence. The potential benefit to the patient should be assessed carefully. Although toxicity of the treatment may be substantial, for most patients, the benefit of therapy outweighed the risk. Chronic hepatitis B: for the treatment of adults with histologically proven compensated chronic active hepatitis B. Patients should be serum HBsAg positive and have evidence of HBV replication (such as serum HBeAg positive) and raised serum alanine aminotransferase (ALT) levels (>3 times the upper limit of the reference range) for at least 6 months. [See Pharmacology for response rate]. Chronic hepatitis C: for the treatment of histologically proven compensated chronic hepatitis due to hepatitis C (HCV antibody positive) in adult patients with persistently elevated serum alanine aminotransferase (ALT). Studies in these patients demonstrate that Intron A Injection therapy can produce normalisation of serum ALT, clearance of serum HCV RNA and improvement in liver histology.

Table of characteristics
Table of characteristics
Active ingredient
Visual appearance Clear to opalescent, colourless to light yellow solution, essentially free of visible particles.
Dosage Form Injection, solution
Route of administration Subcutaneous
Medicine schedule
1 pen with 6 needles (30G 0.3 x 8mm): Prescription Only Medicine, or Prescription Animal Remedy
6 swabs: Not scheduled. Not considered by committee

There is one type of pack available.

Pack type 1
Pack type 1
Type Cartridge
Storage temperature Store at 2 to 8 degrees Celsius
Storage conditions Refrigerate,Do not Freeze
Life time 15 Months
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 May 2018

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo